$101,771.85 research Payment -- Gilead Sciences to Dr. Donna Morgan
This page provides a detailed analysis of a $101,771.85 research payment from Gilead Sciences to Dr. Donna Morgan. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $101,771.85 |
| Payment Type | research |
| Payment Nature | Research |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. Donna Morgan |
| NPI Number | 1167222726 |
| Physician Specialty | Oncology |
| Location | City, CO |
| Date of Payment | 2024-11-28 |
| Related Drug/Device | Imbruvica |
Understanding research Payments
Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.
Related Reports
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.